UNITED STATES PATENT AND TRADEMARK OFFICE

_____

BEFORE THE PATENT TRIAL AND APPEAL BOARD

_____

CELLTRION, INC.,
Petitioner,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

Patent No. 10,464,992

_____

Inter Partes Review No. IPR2023-00462

PATENT OWNER'S UPDATED EXHIBIT LIST

Updated Exhibit List for Inter Partes Review of U.S. Patent No. 10,464,992

Exhibit Description	Exhibit #
Declaration of Dr. Alexander M. Klibanov	2001
Dr. Alexander M. Klibanov *curriculum vitae*	2002
AVASTIN® Label (rev. Sept. 2011)	2003
Declaration of David M. Brown, M.D., *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, IPR2021-00881, Ex. 2050 (Feb. 10, 2022)	2004
MACUGEN® Label (rev. Jul. 2011)	2005
MACUGEN® FDA Approval Letter (Dec. 17, 2004)	2006
AVASTIN® FDA Approval Letter (Feb. 26, 2004)	2007
LUCENTIS® Label (rev. June 2010)	2008
Kyla R. Rodgers & Richard C. Chou, *Therapeutic Monoclonal Antibodies and Derivatives: Historical Perspectives and Future Directions*, 34 BIOTECHNOLOGY ADVANCES 1149 (2016)	2009
Adis R&D Profile, *Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap – Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye*, 9 DRUGS R&D 261 (2008)	2010
Quan Dong Nguyen et al., *A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration*, 113 OPHTHAMOLOGY 1522 (2006).	2011
EYLEA® Label (rev. d Nov. 2011)	2012
U.S. Patent Publication No. 2006/0058234 to Daly et al.	2013
FDA, GUIDANCE FOR INDUSTRY: Q1A(R2) STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS (rev. 2, 2003)	2014
PHARMACEUTICAL FORMULATION DEVELOPMENT OF PEPTIDES AND PROTEINS (Sven Frokjaer & Lars Hovgaard, eds., 2000)	2015
Jonas L. Fast et al., *Physical Instability of a Therapeutic Fc Fusion Protein: Domain Contributions to Conformational and Colloidal Stability*, 48 BIOCHEMISTRY 11724 (2009)	2016
ANTIBODY FUSION PROTEINS (Steven M. Chamow & Avi Ashkenazi, eds. 1999)	2017

Hussein Hollands et al., *Short-Term Intraocular Pressure Changes After Intravitreal Injection of Bevacizumab*, 42 CAN. J. OPHTHAMOLOGY 807 (2007)	2018
Domenico Sanfelice, et al. *Cold Denaturation Unveiled: Molecular Mechanism of the Asymmetric Unfolding of Yeast Frataxin*, 16 CHEMPHYSCHEM 3599 (2015)	2019
Sven Frokjaer & Daniel E. Otzen et al., *Protein Drug Stability: A Formulation Challenge*, 4 NATURE REVIEWS DRUG DISCOVERY 298 (2005)	2020
Somatropin, THE UNITED STATES PHARMACOPEIA 1993 (29th rev., official from Jan. 1, 2006)	2021
International Patent Publication No. 2006/104852 to Dix et al.	2022
U.S. Patent Publication No. 2006/0217311 to Dix et al.	2023
List of References cited by Applicant and Considered by Examiner, U.S. Patent App. No. 16/582,486 (received Mar. 2, 2021 and considered Apr. 12, 2021)	2024
Third-Party Submission Under 37 CFR 1.290, U.S. Patent App. No. 16/582,486 (considered Dec. 31, 2020)	2025
U.S. Patent No. 11,066,458 to Furfine et al.	2026
Russell F. Doolittle, *The Multiplicity of Domains in Proteins*, 64 ANN. REV. BIOCHEMISTRY 1995	2027
Liliana M. Sampaleanu et al., *Three-Dimensional Structure of the Argininosuccinate Lyase Frequently Complementing Allele Q286R*, 40 BIOCHEMISTRY 15,570 (2001)	2028
Arvind K. Pandey et al., Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease, 71 Hypertension, Dec. 26, 2017	2029
Abhibav A. Shukla & Uwe Gottschalk, *Downstream Processing of Fc-Fusion Proteins*, in THERAPEUTIC FC-FUSION PROTEINS (S.M. Chamow et al., eds. 2014)	2030
Terri Davis-Smyth et al., *The Second Immunoglobulin-Like Domain of the VEGF Tyrosine Kinase Receptor Flt-1 Determines Ligand*	2031

Binding and May Initiate a Signal Transduction Cascade, 15 EMBO J. 4919 (1996).	
P17948 VGFR1_Human, available at https://www.uniprot.org/uniprotkb/P17948/entry	2032
P17948 VGFR1_Human, Entry Version 140 (txt) (Jan. 11, 2011), available at https://rest.uniprot.org/unisave/P17948?format=txt&versions=140	2033
Dan Lu et al., *Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies*. 275 J. BIOLOGICAL CHEMISTRY 14321 (2000)	2034
Matthew C. Franklin et al., *The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies*, 19 STRUCTURE 1097 (2011)	2035
P35968 VGFR2_Human, available at https://www.uniprot.org/uniprotkb/P35968/entry	2036
P35968 VGFR2_Human, Entry Version 127 (txt) (Jan. 11, 2011), available at https://rest.uniprot.org/unisave/P35968?format=txt&versions=127	2037
Clifford R. Robinson & Robert T. Sauer, *Optimizing the Stability of Single-chain Proteins by Linker Length and Composition Mutagenesis*, 95 PROC. NATL. ACAD. SCI. USA, 5929 (1998)	2038
Bei Tong et al., *Interdomain Linker Effect on the Mechanical Stability of Ig Domains in Titin*, 23 INT'L J. MOLECULAR SCI. 9836 (2022)	2039
Xiaoying Chen et al., *Fusion Protein Linkers: Property, Design and Functionality*. 65 ADVANCED DRUG DELIVERY REV. 1357 (2013)	2040
Jose I. Casal et al., *Subunit Interface of Triosephosphate Isomerase: Site-Directed Mutagenesis and Characterization of the Altered Enzyme*, 26 BIOCHEMISTRY 1258 (1987)	2041
Tzu-Jing Yang et al, *D614G Mutation in the SARS-CoV-2 Spike Protein Enhances Viral Fitness by Desensitizing It to Temperature-Dependent Denaturation*, 197 J. BIOLOGICAL CHEMISTRY 101,238 (2021)	2042

BIOCHEMISTRY (Jeremy M. Berg et al., eds., 5th ed. 2002)	2043
Declaration of Daralyn J. Durie in Support of this Motion for Admission *Pro Hac Vice* ("Durie Decl.")	**2044 [NEW]**
Declaration of Kira A. Davis in Support of this Motion for Admission *Pro Hac Vice* ("Davis Decl.")	**2045 [NEW]**

Date: October 10, 2023

Respectfully Submitted,

By: /Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287
Morrison & Foerster LLP
425 Market Street
San Francisco, California 94105
Tel: (415) 268-6053
ABrausa@mofo.com

Certificate of Service (37 C.F.R. § 42.6(e)(4))

I hereby certify that the attached UPDATED EXHIBIT LIST were served on the date listed below via electronic mail upon the following counsel of record for Petitioner.

Lora M. Green (USPTO Reg. No. 43,541)
Yahn Lin Chu (USPTO Reg. No. 75,946)
Robert Cerwinski (pro hac vice, pending)
Aviv Zalcenstein (pro hac vice, pending)
Brigid Morris (pro hac vice, pending)
David Kim (USPTO Reg. No. 69,503)
GEMINI LAW LLP
40 W 24th Street, Suite 6N
New York, NY 10010
Tel.: 917-915-8832
Email: lgreen@geminilaw.com
Email: fchu@geminilaw.com
Email: rcerwinski@geminilaw.com
Email: azalcenstein@geminilaw.com
Email: bmorris@geminilaw.com
Email: dkim@geminilaw.com

Dated: October 10, 2023

/Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287